Navigation Links
Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
Date:6/10/2011

ma GmbH), a novel, highly efficient and portable aerosol delivery system enabling more effective distribution in the lungs.

ARIKACE has been granted orphan drug status in the United States by the FDA, and has received an orphan drug designation in Europe by the European Medicines Agency for the treatment of Pseudomonas infections in patients with CF.  In addition, the Company recently filed for orphan drug designation for NTM lung infections in the United States and plans to do so in the European Union once the process is completed in the United States.

About The Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease.  The CF Foundation is a donor-supported nonprofit organization.  For more information, go to www.cff.org.

About eFlow® Technology and PARI Pharma

ARIKACE is delivered by an investigational eFlow® Nebulizer System developed by PARI Pharma and optimized specifically for ARIKACE.  The optimized, investigational eFlow Nebulizer System uses eFlow Technology to enable highly efficient aerosolization of medication including liposomal formulations via a vibrating, perforated membrane that includes thousands of laser drilled holes.  Compared to other nebulization technologies, eFlow Technology produces aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible period of time.  eFlow® Technology is
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Precision Therapeutics Demonstrates Utility of Multi-Gene Predictors in Predicting Chemotherapy Response for Breast Cancer Patients
2. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
3. Argos Therapeutics Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
4. Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization
5. VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis
6. PROMUS Element™ Stent Demonstrates Exceptional Safety and Effectiveness in PLATINUM Small Vessel Study
7. Intravenous (IV) Administration of Cempra Pharmaceuticals Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
8. HERCULES Trial Demonstrates Significant Reduction in Systolic Blood Pressure While Revealing Marker in Hypertensive Patients Does Not Predict Outcomes of Renal Artery Stenting
9. SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease
10. Baxa Corporation Demonstrates End-to-End Environmental Stewardship
11. REMEDIAL II Trial of PLCs RenalGuard® Demonstrates Greater Efficacy than Current Standard of Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015  goBalto, Inc., ... solutions, announced today unprecedented growth in serving pharmaceutical, ... intense pressure to speed clinical trials and restrain ... and paper-based methods have stalled these efforts," said ... status of clinical trials has encouraged Industry leaders, ...
(Date:7/1/2015)... , July 1, 2015 Prismic Pharmaceuticals, Inc., ... FDA-regulated medical foods, today announced the election of ... to its Board of Directors. Commenting ... Peter Moriarty , Chairman and CEO of Prismic, ... and Martin Simonetti have accepted our invitation ...
(Date:7/1/2015)... 2015  Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ... and commercialization of proprietary compounded drug formulations, today ... stock market closing bell on Thursday, July 2, ... its Go Dropless™ campaign since its launch in ... performed annually in the U.S. and more than ...
Breaking Medicine Technology:goBalto Triples Sites Managed, Further Reinforcing Market Leadership Position 2Joseph Krivulka and Martin Simonetti Join Board of Prismic Pharmaceuticals 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 3Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 4
...     " The ...   with   their urban counterparts in adopting technology to improve ... spill shows risk of online health records . " ... its current challenges? Ambitious national healthcare IT programmes and initiatives are ...
... RALEIGH, N.C., Aug. 22, 2011 BioDelivery Sciences International, ... the commercial launch and availability of ONSOLIS (fentanyl buccal ...   (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) ONSOLIS is ... it will be marketed as BREAKYL) for the management ...
Cached Medicine Technology:Innovations in E-Health & Informatics Europe: The Need for a European EHealth Strategy 2BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada 2BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada 3
(Date:7/1/2015)... Japan (PRWEB) , ... July 01, 2015 , ... ... 2015 of a new extraction plant for Linablue®, Spirulina-derived natural blue food coloring. ... Nutritionals, LLC, the DIC Group’s U.S. Spirulina* production base, began in May 2014. ...
(Date:7/1/2015)... Plainsboro, NJ (PRWEB) , ... July 01, 2015 ... ... Cannon , the global cancer enterprise of Hospital Corporation of America (HCA), as ... treatment and research, OncLive announced today. , With this new partnership, OncLive’s ...
(Date:7/1/2015)... ... July 01, 2015 , ... The 28th annual Charity Horse ... Saturday, July 11, 2015, at 6 p.m. in Pugh Bourne Park, 343 Oakfield Road. ... rides, a petting zoo, an Elvis impersonator, a silent auction and concessions. , Horses ...
(Date:7/1/2015)... Florida (PRWEB) , ... July 01, 2015 , ... ... for society,” said lead author Lisa Stolzenberg, a Professor in FIU’s School of ... juveniles aged 12 to 17 years who participated in the National Survey on ...
(Date:7/1/2015)... ... July 01, 2015 , ... Element Blue ™, a ... that it has received trademark protection for its SensorInsight® computer software platform. SensorInsight® ... from multiple sources providing an environment where users can view and compare real-time ...
Breaking Medicine News(10 mins):Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4
... not express their requests feel less satisfied with their physicians and ... a patient everything on his mind. One may feel anxious and ... seem rushed, or it may be that the relationship between the ... could be.// ,Researchers at the University of Texas have ...
... fertility among infertile men, a new report suggests.The study ... genetic or medical risk factors for infertility. ,The ... because they involved a selected population of infertile men, ... say the dramatic nature of the observed changes in ...
... fights battle towards eternity and hence the researches over ... existance of newer solutions to fight for the same. ... , Dr. Simona Giampaoli, from the Istituto Superiore di ... come out with a view that Heart rate appears ...
... Teflon frypans and other cooking utensils may damage the ... one of a class of chemicals known as fluorinated ... ovens and combustion engines. ,However, when heated, ... acid (TFA) which is toxic to plants and does ...
... in elderly people was carried out by researchers in the ... the link between drinking and the health of their brains. ... ,It has been found that any level of ... on brain function. But light-to-moderate drinkers had fewer 'silent' strokes ...
... much of stress,a self-perpetuating cycle of factors can fuel the ... gain often piles up around the abdomen, which boosts the ... ,One doctor states, that people may be able to ... when the body is vulnerable to stress and choosing the ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: